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were evaluated based on US and European PRO/HRQOL guidance criteria.RESULTS:
The review identified 8 HRQOL measures used with EB patients: 3 generic (SF-36;
EQ-5D, EQ-5DY); 4 dermatology-specific (DLQI, CDLQI, DQOLS, Skindex); and 1 EB-
specific (QOLEB). Only the CDLQI and QOLEB were specifically designed for pediat-
ric populations (ages 4-16 and 10 years, respectively). The QOLEB was the only
instrument for which content was derived from EB patients; 26 patient interviews
were conducted, of which 9 were with patients 18 years. Despite pediatric input
during development, not all QOLEB content is relevant to children/adolescents;
items assessing family and financial impact are not appropriate for these respon-
dents. Psychometric properties have been established among pediatric EB patients
only for the QOLEB (convergent validity [DLQI: R  0.774]; internal consistency [
0.931]; test-retest reliability [R  0.843]). CONCLUSIONS: Few published measures
meet current regulatory standards for HRQOL evaluation in pediatric EB patients.
Given the age range for EB, an HRQOL instrument that evaluates age-appropriate
concepts was not identified. Further research is needed to document and assess
HRQOL concepts in pediatric patients with EB.
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RECRUITMENT COSTS AND EFFICIENCY VARIES WITH CONDITION/ PATIENT
POPULATION
Pumford N, Wade A, Crawford G
Patients Direct, Glasgow, UK
OBJECTIVES:To compare the rate and cost of traditional versus on line recruitment
methods to medical surveys in 2 different patient populations. METHODS: We
compared traditional to on line advertising in 2 separate projects (conducted in the
UK) across the same time period using the same internet and social media recruit-
ment methodologies allowing a comparison of the costs and effectiveness. By look-
ing at 2 quite distinct populations – the first being cholesterol lowering agents, thus
an older age with cardiovascular disease and the second women with problem
periods, hence a younger and otherwise healthy group we could evaluate the re-
cruitment methods. RESULTS: All costs are direct payments and exclude labour;
Cholesterol lowering agents; Traditional methods – recruitment through chain of
pharmacists using leaflets; 303 patients recruited over 9 months; cost/ survey £3.94.
Internet/Social media – adverts placed on facebook.com, google and third party ad
network; 3812 visitors to website; cost/ visitor £0.23; 572 survey completions over 11
weeks; cost/ survey £1.53. Problem Periods: Traditional methods – magazine ad-
verts, exhibition stand, press releases; 232 Women recruited over 8 weeks; Cost/
survey £18; Internet/Social Media; 6000 visitors to website over 11 weeks; cost/
visitor £0.30; 1534 survey completions over 11 weeks; cost/ survey £1.51.
CONCLUSIONS: Whilst traditional methods of recruiting participants were suc-
cessful, they were generally slower and cost more per person recruited. Internet
advertising and use of social media sites offers the potential of rapid, cost effective
recruitment. This result however does not tell us if the traditional adverts were
making it more likely people would search on line, thus driving the on line recruit-
ment or if the statins population (our statin population mean age was 62) is repre-
sentative of older age groups where it is anticipated that more traditional adver-
tising would be required.
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DEVELOPMENT OF A GENERIC SPANISH VERSION OF THE MODIFIED
MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) DIARY
Boucher F1, Joulain F2, Mesa R3, Emanuel R4
1MAPI Institute, Lyon, France, 2Sanofi-Aventis, Massy, France, 3Mayo Clinic, Scottsdale , AZ,
USA, 4Mayo Clinic, Scottsdale, AZ, USA
OBJECTIVES: The MFSAF Diary is a refined version of the Myeloproliferative Neo-
plasm Symptom Assessment Form (MPN-SAF) designed to measure the impact of
MF-related symptoms. Six symptoms are rated on a scale from 0 (absent) to 10
(worst imaginable): 1) night sweats; 2) itching (pruritus); (3) abdominal discomfort;
4) filling up quickly when you eat (early satiety); 5) pain under ribs on left side; and
6) bone or muscle pain. The objective of this study is to present the development of
a generic Spanish version to be used in Mexico, Spain, and the USA. METHODS: 1)
Concept definition; 2) Development of a Spanish translation in Mexico, Spain, and
the USA; 3) Creation of a reconciled Spanish version using the three Spanish ver-
sions as a basis; 4) Backward translation of the reconciled version; 5) Cognitive
interviews with five patients in each country. RESULTS: The development of the
reconciled version did not show major difficulties. For instance, “bone or muscle
pain” was translated as “dolor en los huesos o músculos,” and well understood by
patients. It was agreed that the use of nouns (huesos/musculos for bones/muscles)
was more appropriate as people with a very low education level might have diffi-
culties to understand adjectives such as “óseo” (osseous). Patients had difficulties
with “itching (pruritus)” translated at first by “comezón/prurito/picor.” It was im-
possible to find a common term for the three countries, and a compromise was
found with the use of the association of “comezón/picor,” with “comezón” widely
used in Mexico and “picor” in Spain. “Prurito” could not be chosen for all countries
since it was problematic for Spanish patients. CONCLUSIONS: The creation of a
generic Spanish version of the MFSAF Diary was made possible by developing
Spanish versions in Mexico, Spain, and the USA, and accepting compromises when
common terms could not be used.
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OBJECTIVES: The Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS) was initially developed as a neuropsychological screening tool for
dementia. It is now commonly used to screen for abnormal cognitive decline across
a range of clinical populations. The Picture Naming subtest, a confrontation-nam-
ing task requiring subjects to name 10 line drawings, is used to assess basic verbal
functions and language skills. This abstract presents the challenges faced during
the translation of 40 pictured words into 13 languages (Bulgarian, Chinese for Tai-
wan, Czech, English and French for Canada, German, Hindi, Hungarian, Kannada,
Korean, Marathi, and Spanish for Mexico and the USA).METHODS: In each country,
a thorough forward translation was performed including two translators and a
speech therapist, all native speakers of the target languages. Criteria for selecting
substitute items were developed in instances where literal translations would be
culturally inappropriate (i.e., substitutes should match the frequency of use of the
source terms, belong to the same semantic field, be familiar to all people and easily
drawn). Finally, a clinician’s review was performed. RESULTS: Eleven of the 40
source words had to be substituted. The languages that required the most substi-
tutions were Bulgarian, Chinese, Hindi, Hungarian, Kannada, Korean, and Marathi,
whereas few substitutions were needed for languages culturally close to US English
(Canadian English and French, German, and US Spanish). The most culturally prob-
lematic picture words were “Barn” and “Toboggan/Sled.” “Barn”, for example, was
replaced by the word “House” and its corresponding picture in eight out of the 13
languages. CONCLUSIONS: This project demonstrates that translating pictured
words meaningfully in a clinical research context requires the collaboration of the
developer to correctly interpret the original, translators for their knowledge of
language, a speech therapist for his/her understanding of the word’s function, and
a clinician to validate the chosen word’s relevance.
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OBJECTIVES: Multiple sclerosis (MS) is the most common disabling neurological
disease of young adults and is associated with significant economic and Health-
Related Quality-of-Life burden. Cost-effectiveness models in MS are commonly
structured on health states reflecting progressing disease severity, represented by
scores on the Expanded Disability Status Scale (EDSS) 0-9, whereby single utility
and cost values are applied to each EDSS state in the model. Using EQ5D-5L results
from an Irish outpatient cohort of 212 patients with MS, the aim of this study was
to model the relationship between utility and EDSS. METHODS: The association
between disease severity and quality of life in MS was determined using a piece-
wise linear regression where EDSS scores were treated as discrete indicator vari-
ables. The model was fitted in WinBUGs; with the constraint that increasing EDSS
score is associated with a disimprovement in quality of life. The mapping between
utility and EDSS can be determined from these data. RESULTS: Disease severity
(EDSS) had a significant negative impact on HRQoL (p0.001). A non-linear decline
in utility was observed with the most dramatic declines occurring once patients
reach EDSS 6 and beyond. Mean utility values from the piecewise linear regression
ranged from 0.88 (EDSS 0) to 0.22 (EDSS 9), and were associated with smaller
standard errors than a simple linear model. The greatest utility decrease was be-
tween EDSS 6 and 7 (0.15) and EDSS 7 and 8 (0.41). CONCLUSIONS: The decline
in HRQoL in MS is multifactorial, but can be explained primarily by the severity of
the disease. The application of one linear model to the data was not justified. The
piecewise regression improved model efficiency and reduced sampling variability
by utilising the trends in utility decline between EDSS states.
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OBJECTIVES: To explore how patients and payers perceive value and risk and
investigate the role of patient-reported outcomes.METHODS:Quintiles surveyed a
variety of US and UK stakeholders including: an online survey of payers (US man-
aged care, UK National Health Service) and a telephone survey of adult patients
being treated for a chronic disease.RESULTS:Between January and March 2012, 144
payers (75 US, 72 UK National) and 1009 patients (509 US and 500 UK) were sur-
veyed. In general, payers were more optimistic that the quality of health care
would be improved 10 years from now than patients (68% US / 66% UK payers vs.
49% US / 38% UK patients). From the payer perspective, over 80% of payers support
use of risk sharing for: 1) population-based performance guarantees (i.e., coverage
dependent on meeting a benefit target) and 2) Coverage with Evidence Develop-
ment (CED) deals (i.e., future review based on real-world product evidence). High
administration costs (66%), difficulties in agreeing on definition of success (67%),
and difficulties in accurately measuring treatment success (63%) are among main
problems. With 77% of US and 73% UK payers supporting the shift to a more pa-
tient-oriented approach to treatment assessment, it is not surprising that PROs are
the metric most commonly used to assess risk/benefit (60% and 71% respectively).
Patients are in agreement with payers that PROs are most important in how they
evaluate the value of medicines (51% US, 60% UK). Other important drivers of
patient value: helping people live longer (14% US, 24% UK) and affordability (25%
US, 2% UK). CONCLUSIONS: Payers and patients agree that use of PRO data is
critical to assessing value and benefit-risk for prescription medicines. The shift to
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patient-centered treatment assessments and growth in risk sharing assessments
will further increase the need for real-world PRO data.
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EXPLORING PATIENT PERCEPTIONS OF, AND PREFERENCES FOR, PAIN
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OBJECTIVES: Scales measuring perceptions of pain can include numeric rating
scales (NRS), visual analogue scales (VAS) and descriptor scales using words (ad-
jectival). With the increased use of electronic data capture in clinical trial settings,
such scales have been migrated to numerous platforms. After conducting a brief
literature review, there was found to be a lack of research on the impact that
migration of such pain scales can have on the efficacy of the scales. The objective
of this study was to deploy three pain scales in different formats and on different
platforms, and to explore preferences and perceived differences in patients who
experience daily pain. METHODS: Twelve participants diagnosed with a range of
conditions resulting in pain were interviewed in a qualitative interview setting. All
participants completed three pain scales in different formats: NRS (11-, 9-, and
7-points; portrait/ landscape), VAS (horizontally/ vertically; portrait/ landscape)
and adjectival scale (increasing/ decreasing severity). All scales were presented in
three modes of administration: paper, handheld device and tablet device. Partici-
pants were asked about perceived differences and their preferences of the different
scales, formats, and modes of administration. RESULTS: The NRS and adjectival
scale were preferred equally (n5). Participants expressed an almost unanimous
preference for the 11-point NRS and increasing severity adjectival scale, across all
administration modes. In contrast, the VAS was the least preferred scale (n7) due
to difficulty with interpretation. Participants expressed no usability problems with
the tablet or handheld devices, but the tablet was preferred overall because of the
bigger screen. CONCLUSIONS: Although the sample size makes generalising these
findings difficult, this exploratory study suggests that the preferred pain scales
may provide higher quality data as they are easier to interpret, and therefore mi-
nimise error and patient burden. Further evidence, particularly quantitative, is
required to support these preliminary findings.
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OBJECTIVES: Effective translation and adaptation of neuropsychological assess-
ments is paramount to the successful collection of data in a global context. The
structure and content of neuropsychological assessments requires specific pro-
cesses for translation and adaptation to ensure appropriate understanding in each
target language. Word list adaptation requires particular consideration, as various
criteria must be met within and between wordlists – including but not limited to
frequency, familiarity and cultural relevance to the target population, number of
syllables, and avoidance of homonyms and repeated words. This review highlights
important considerations for creation of target language word lists, and solutions
for determining appropriate adaptation methodologies. METHODS: A review of
previous translations of neuropsychological assessments, such as the ADAS, FC-
SRT, RBANS, MoCA, and MMSE, was performed. A review of translation procedures,
developer involvement, guidelines for adaptation, translation methodology, lin-
guistic decisions, and word list creation was conducted. RESULTS: Key solutions to
ensure successful adaptation of wordlists include: 1) Outline all criteria used to
develop the English word lists and assessment, 2) Create clear guidelines for adap-
tation of word lists in collaboration with the developer, if guidelines are not already
available, 3) Employ a specialized project team of project managers, native-speak-
ing medical linguists, and native-speaking neuropsychologists possessing exten-
sive expertise in the relevant neuropsychological assessments. 4) Depending upon
the assessment and the context of use, additional testing of the word lists with
local populations to ensure comprehension may be warranted. CONCLUSIONS:
Neuropsychological assessments and word lists require specialized translation
and adaptation methodologies to ensure appropriate comprehension by the target
population. Developer involvement in the creation of adaptation guidelines, and
neuropsychologist involvement in the adaptation process are critical to ensuring
adaptation is conducted appropriately. Further research is required to outline clear
guidelines for situations requiring additional testing of the word lists with local
populations to ensure comprehension.
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OBJECTIVES:Mapping or cross-walking is an accepted methodology for calculating
utilities. Different models have been proposed for mapping from disease-specific
quality-of-life (QOL) measures to generic QOL measures. Much of this work has
been done using data from rheumatoid arthritis cohorts and using measures spe-
cific to RA. The objectives of this study are to test various statistical models to
determine which provides the best fit for a psoriatic arthritis (PsA) cohort using
both newly developed composite disease measures and established measures. The
study also aimed to determine whether the composite disease measures provide a
better estimate of utility over other measures and which components of the com-
posite measures influence the relationship with QOL. METHODS: The data was
made available from the Group for Research and Assessment of Psoriasis and Pso-
riatic Arthritis (GRAPPA) which collected data from an international cohort of PsA
patients. Different regression models were used to estimate the relationship be-
tween the generic QOL measure, SF-6D and disease specific measures (HAQ,Com-
posite Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score
(PASDAS) and the Arithmetic Mean Desirability Function Score (AMDF). Model fit
was determined using the R2 statistic, root mean square error, Akaike information
criterion; regression coefficients are also presented. RESULTS: The optimal model
for each of the disease specific measures and SF-6D was a multiple regression
model. The difference in model fit between the linear and multiple regression
models was greatest for the composite disease measures specific to PsA. The CPDAI
and AMDF provided the best fit to utility score followed by the PASDAS.
CONCLUSIONS: PsA is a heterogeneous disease for which composite disease mea-
sures may be more appropriate than measures such as the HAQ. This study pro-
vides mapping coefficients, allowing utility estimation from these measures which
may be collected in trials where no preference-based utility measure has been
used.
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OBJECTIVES: To highlight some of the common areas that require particular atten-
tion when preparing clinical outcome assessment (COA) dossiers, suitable for FDA
regulatory label claims, with a particular focus on clinician-reported outcome
(ClinRO) measures. The FDA has provided guidance for the use of Patient-Reported
Outcome (PRO) measures for relevant endpoints in clinical trials to support label
claims (FDA, 2009). Although several authors have indicated that the standards
used to evaluate PRO’s will apply to all COA’s (Burke, 2011; Gwaltney, 2012), the FDA
have not published guidelines on ClinRO measures to support label claims. This is
surprising given that the ratio of label claims based on ClinRO’s is approximately
three ClinRO’s to every PRO measure (Burke, 2010). METHODS: We conducted a
review of the literature to ascertain the general level of use of ClinRO’s and to find
examples of widely used ClinRO’s. The available evidence for these ClinRO’s was
then assessed by the standards of the PRO guidance, specifically in relation to
content and construct validity, reliability and other psychometric properties.
RESULTS: The literature review revealed that ClinRO’s are common endpoints in
clinical trials. However, it was also apparent from the sample of ClinRO’s reviewed,
that they fail to meet the evaluative standards prescribed by the FDA particularly in
being “well defined and reliable”. CONCLUSIONS: ClinRO’s used as endpoints in
clinical trials to support FDA label claims may lack the required evidence set out in
the FDA PRO guidance document. Specifically, many ClinRO’s have been developed
by clinicians, and widely accepted by clinical peers, without undergoing psycho-
metric evaluation. If the FDA were to evaluate ClinRO’s to the same standards as
PRO’s, the ratio of label claims between ClinRO’s and PROs may decrease signifi-
cantly.
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OBJECTIVES: Osteoarthritis (OA) also known as degenerative arthritis or degener-
ative joint disease, is a group of mechanical abnormalities involving degradation of
joints. The daily-life of OA patient is considerably disturbed. The burden’s concept
assesses the individual burden, measuring the patient’s disability generated by the
disease in a broad sense.The aim of our study was to explore, using a question-
naire, how the burden of the OA affected a daily life, with the objective to better
anticipate difficulties and thus provide better care METHODS: The development of
the questionnaire we propose here was inspired by the construction of general
QoL- questionnaires. Two steps are required for the development:, the creation in
three stages following a strict methodological process involving a multidisciplinary
team (doctors, social workers) and patients with OA who were interviewed; Sec-
ondly, the validation of the questionnaire by testing its reliability, its construct
validity and its reproducibility. A cognitive debriefing was conducted to ensure its
reproducibility. RESULTS: A population of 198 patients with OA was enrolled to
answer to the questionnaire,( with SF12 and PGWI). We obtain a questionnaire
called “Burden-Osteoartritis-New-Scale-BONeS”. Exploratory assessments real-
ized with a population showed that the concept of burden could be structured
around 5 components: autonomy, daily life, family and personal relationships,
work and psychological impact. 41 preliminary items were identified at the end of
the verbatim. A final analysis managed to reduce to 28 items and a cognitive de-
briefing allowed to ensure its reproducibility. CONCLUSIONS: Chronic pathologies
such as OA which remains a rare and incapacitating illness are difficult to assess by
clinical or QoL aspects alone as their impact can be multidimensional. “BONeS”
takes them all into consideration in order to explain every angle of the handicap
generated. Our next objective is to develop the “BONeS” in German, Italian and
Spanish with a cross cultural validation.
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